DelveInsight's Vitiligo Market Insights report includes a comprehensive understanding of current treatment practices, vitiligo emerging ...

DelveInsight's TYK2 Inhibitors Market Size, Target Population, Competitive Landscape & Market Forecast report includes a ...

Pfizer said its full-year profit should benefit from cost cuts across its research and manufacturing operations after posting ...

Industry experts from Amazon Business, Bristol Myers Squibb, and SMBC Americas discuss AI-driven procurement strategies at BI ...

This meta-analysis challenges the randomized FRAIL-AF results, but caution is needed when reconciling the discrepant findings ...

As part of a "strategic alignment" of its pipeline, BioNTech is laying off 90 workers in R&D and corporate roles across two sites in Maryland and Massachusetts, a spokesperson told Fierce. | As part ...

The supplemental New Drug Application is supported by data from the Phase II TRANSCEND FL trial (NCT04245839), which showed ...

Building on bispecific antibodies, four of which have been approved by the FDA to treat relapsed/refractory multiple myeloma, ...

CEO Albert Bourla said on Tuesday that he and other pharma executives discussed President Donald Trump’s recent call for big pharma to offer direct-to-consumer marketing as part of his Most Favored ...

The administration wants drugmakers to bring medication prices more closely in line with the Most-Favored Nation pricing approach.

In this video, Philip J. Mease, MD, discusses results from phase 3 clinical trials of deucravacitinib for psoriatic arthritis, presented at the EULAR 2025 Congress.

The FDA granted priority review to the application and will decide whether to approve the treatment by Dec. 5.